DOCSLIB.ORG

C-Peptide Concentrations in Patients with Type 2 Diabetes Treated with Insulin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
C-Peptide Concentrations in Patients with Type 2 Diabetes Treated with Insulin Diabetes & Metabolic Syndrome: Clinical Research & Reviews 13 (2019) 3099e3104 Contents lists available at ScienceDirect Diabetes & Metabolic Syndrome: Clinical Research & Reviews journal homepage: www.elsevier.com/locate/dsx C-peptide concentrations in patients with type 2 diabetes treated with insulin * Mehmet Uzunlulu a, Aytekin Oguz a, Müzeyyen Arslan Bahadir b, Ayse Naciye Erbakan c, , Mirac Vural Keskinler b, Banu Alpaslan Mesci a a Istanbul Medeniyet University, Goztepe€ Training and Research Hospital, Istanbul, Turkey b Goztepe€ Training and Research Hospital, Istanbul, Turkey c Nisa Hospital, Istanbul, Turkey article info abstract Article history: Aims: To determine beta cell reserves of patients with type 2 diabetes who are treated with insulin by Received 25 July 2019 using fasting C-peptide concentrations and to investigate the clinical features related to C-peptide Received in revised form concentrations. 14 November 2019 Materials and methods: Patients with type 2 diabetes, who were using insulin as monotherapy or in Accepted 15 November 2019 combination therapy, were divided into three groups; those with an insufficient beta cell reserve (C- peptide: <0.5 ng/mL), borderline reserve (C-peptide: 0.5e2 ng/mL) and sufficient reserve (C-peptide:> Keywords: 2 ng/mL). Type 2 diabetes ± C-peptide Results: In the 249 patients (mean age, 61.77 9.34 years; 40.6% male), the mean duration of diabetes ± Beta-cell reserve was 13.9 8.43 years. The mean HbA1c concentrations, fasting glucose and C-peptide concentrations Insulin use were 8.88 ± 1.87%, 184.29 ± 77.88 mg/dL and 1.95 ± 1.37 ng/mL, respectively. Fifty-seven percent of patients (n ¼ 142) had a borderline beta cell reserve and 37% (n ¼ 92) had high C-peptide concentrations. Only 6% of patients (n ¼ 15) had an insufficient beta cell reserve. C-peptide levels were positively correlated with waist circumference (r: 0.282; p ¼ 0.001), hip circumference (r: 0.251; p ¼ 0.001), body mass index (r: 0.279; p ¼ 0.001), fasting glucose concentrations (r: 0.309; p ¼ 0.001) and triglyceride concentrations (r: 0.358; p ¼ 0.001). Conclusion: In this study, almost all patients with type 2 diabetes using insulin were found to have sufficient or borderline beta cell reserves and insulin resistance-related parameters were prominent in those with adequate beta cell reserve. Clinical trials no: NCT04005261 © 2019 Diabetes India. Published by Elsevier Ltd. All rights reserved. 1. Introduction medications [3]. It has been suggested that C-peptide concentra- tions correlate with microvascular and macrovascular complica- C-peptide is secreted in equimolar amounts with insulin from tions in both type 1 and type 2 diabetes and can be a reliable pancreatic beta cells and is reported to be a more useful laboratory indicator for predicting future insulin needs [4e6]. In patients with parameter than insulin in evaluating endogenous insulin reserve type 2 diabetes, initiation of insulin therapy is indicated in several [1,2]. C-peptide measurement can be used in the differential diag- conditions such as severe insulin resistance, acute metabolic de- nosis of type 1 and type 2 diabetes, for the identification of patients compensations, surgery, pregnancy, and progression of diabetic with maturity-onset diabetes of the young (MODY) or latent complications, and also when glycemic control cannot be achieved autoimmune diabetes of adults (LADA); for the detection of abso- with effective lifestyle regulation and non-insulin antidiabetic lute insulin deficiency; and in planning timely changes of treatment medications [7,8]. At that point, a low C-peptide level is considered in patients with diabetes using either insulin and other diabetic to be a reliable parameter in the decision to start insulin therapy except in extreme hyperglycemic conditions. In our “National Diabetes Consensus Group Diabetes Diagnosis and Treatment” guideline, it is recommended that glycated he- * Corresponding author. E-mail address: [email protected] (A.N. Erbakan). moglobin (HbA1c), as well as C-peptide concentrations, should be https://doi.org/10.1016/j.dsx.2019.11.010 1871-4021/© 2019 Diabetes India. Published by Elsevier Ltd. All rights reserved. 3100 M. Uzunlulu et al. / Diabetes & Metabolic Syndrome: Clinical Research & Reviews 13 (2019) 3099e3104 considered in the planning of type 2 diabetes treatment [9]. When, evaluate the relationship between fasting C-peptide and clinical in daily practice, C-peptide concentrations are observed to be features. normal or high in patients with type 2 diabetes who use insulin, it causes confusion about the treatment decision and raises the 2.2. Anthropometric measurements question as to whether the patients’ insulin use is necessary. The aim of this study was to investigate c-peptide concentra- Body weight, waist circumference, and height were measured tions in patients with type 2 diabetic using insulin as a mono- by the same physician using standard measuring instruments. therapy or as part of combination therapy, and to examine the Waist circumference was measured while the patient was standing, clinical features associated with predetermined C-peptide at the narrowest part of the waist with a slight expiration on the concentrations. midpoint between the lowest rib and the iliac crest, as defined by the World Health Organization. Hip circumference was measured at 2. Material and methods the level of the widest circumference over the greater trochanters. Body mass index (BMI) was calculated as weight (in kilograms) This prospective, observational clinical study was conducted on divided by height (in square meters). Blood pressure was obtained consecutive patients with type 2 diabetes aged 18 years or older using an appropriate mercury sphygmomanometer (based on who presented to the Diabetes Outpatient Clinics of Istanbul Korotkoff Phase I and Phase V sounds) on both arms with the pa- Medeniyet University Goztepe Training and Research Hospital be- tient in a comfortable sitting position after at least a 10-min rest. tween November 1st, 2018, and February 1st, 2019. Informed The second measurement was performed on the arm with a higher consent was obtained from all subjects included in the study. The value. Two measurements were taken at least 3 min apart and trial protocol was approved by the hospital ethics committee averaged to provide the values for systolic and diastolic pressure. (October 24, 2018; 2018/0396) and conducted in accordance with the Declaration of Helsinki. 2.3. Analytical measurements Sample size: Assuming a ¼ 0.05 and 80% power, 249 subjects were included in the study using the simple random sampling Fasting glucose concentrations were determined using the method. hexokinase method. Serum creatinine was assayed using the ki- Inclusion criteria: Patients with type 2 diabetes who had been netic Jaffe method. For alanine transaminase (ALT) concentrations, treated with insulin as a monotherapy or as a component of com- an enzymatic (without P-50-P, NADH) method was used. Fasting bination therapy for at least 3 months. plasma total cholesterol, HDL and LDL cholesterol and triglyceride Exclusion criteria: Diagnosis of other types of diabetes, end- concentrations were determined using enzymatic methods (Abbott stage renal failure, history of renal transplantation, diabetic acute Architect c16000 and c8000, Abbott). A Tosoh HLC-723 G8 (Tosoh metabolic decompensation, decompensated heart failure, G8) (Tosoh, Japan) (variant-mode) ion exchange high-performance advanced liver disease, pregnancy, acute or chronic pancreatitis, liquid chromatography (HPLC) system was used for HbA1c mea- pancreatic carcinoma, acute infections, use of medications that surements. The C-peptide was measured using a chem- might affect glucose regulation (e.g. corticosteroids). iluminescence microparticle immunoassay in the Abbott Architect Primary endpoint: Determination of C-peptide concentrations I2000 (Abbott Laboratories, Abbott Park, IL, USA) autoanalyzer. in patients with type 2 diabetes using insulin to evaluate pancreatic Glomerular filtration rate (GFR) was calculated using the beta cell reserve and compare clinical characteristics for C-peptide Chronic Kidney Disease Epidemiology Collaboration equation concentrations. (CKD-EPI) formula [10], and the presence of proteinuria was Secondary endpoint: Assessing the correlation between fasting determined using the protein/creatinine ratio in spot urine. C-peptide concentrations and the clinical features of patients with type 2 diabetes treated with insulin. 2.4. Statistical methods 2.1. Study design Statistical analysis was performed using the Number Cruncher Statistical System NCSS (Number Cruncher Statistical System) Duration of diabetes, demographic characteristics, comorbid- NCSS) version 2007 software (Kaysville, Utah, USA). The normal ities, treatment characteristics, and duration of medication use distribution of quantitative data was tested by using the were recorded for participants who met the inclusion criteria. The Kolmogorov-Smirnov and Shapiro-Wilk tests and graphical evalu- patients’ diabetes type, their medications, the dose of their medi- ations. For groups with normal distribution, one-way analysis of cations, and the regularity of use was further investigated using the variance (ANOVA) was used for multiple groups and the Bonferroni hospital prescription system and the National Medula electronic test was used to compare two groups of independent samples. For prescription system (//medeczane.sgk.gov.tr/doktor/login.jsp). groups
Load more

Recommended publications
  • A Comparative Survey of the RF-Amide Peptide Superfamily
    EDITORIAL published: 10 August 2015 doi: 10.3389/fendo.2015.00120 Editorial: A comparative survey of the RF-amide peptide superfamily Karine Rousseau 1*, Sylvie Dufour 1 and Hubert Vaudry 2 1 Laboratory of Biology of Aquatic Organisms and Ecosystems (BOREA), Muséum National d’Histoire Naturelle, CNRS 7208, IRD 207, Université Pierre and Marie Curie, UCBN, Paris, France, 2 Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, INSERM U982, International Associated Laboratory Samuel de Champlain, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Mont-Saint-Aignan, France Keywords: RF-amide peptides, receptors, evolution, functions, deuterostomes, protostomes The first member of the RF-amide peptide superfamily to be characterized, in 1977, was the cardioexcitatory peptide, FMRFamide, isolated from the ganglia of the clam Macrocallista nimbosa (1). Since then, a large number of such peptides, designated after their C-terminal arginine (R) and amidated phenylalanine (F) residues, have been identified in representative species of all major phyla. The discovery, 12 years ago, that the RF-amide peptide kisspeptin, acting via GPR54, was essential for the onset of puberty and reproduction, has been a major breakthrough in reproductive physiology (2–4). It has also put in front of the spotlights RF-amide peptides and has invigo- rated research on this superfamily of regulatory neuropeptides. The present Research Topic aims at illustrating major advances achieved, through comparative studies in (mammalian and non- mammalian) vertebrates and invertebrates, in the knowledge of RF-amide peptides in terms of evolutionary history and physiological significance. Since 2006, by means of phylogenetic analyses, the superfamily of RFamide peptides has been divided into five families/groups in vertebrates (5, 6): kisspeptin, 26RFa/QRFP, GnIH (including LPXRFa and RFRP), NPFF, and PrRP.
    [Show full text]
  • TRH-Like Peptides
    Physiol. Res. 60: 207-215, 2011 https://doi.org/10.33549/physiolres.932075 REVIEW TRH-Like Peptides R. BÍLEK1, M. BIČÍKOVÁ1, L. ŠAFAŘÍK2 1Institute of Endocrinology, Prague, Czech Republic, 2Urology Clinic, Beroun, Czech Republic Received September 6, 2010 Accepted October 8, 2010 On-line November 29, 2010 Summary of the leaders working in the area concerning the TRH TRH-like peptides are characterized by substitution of basic research was Professor V. Schreiber from Prague, Czech amino acid histidine (related to authentic TRH) with neutral or Republic, which already in 1959 formulated the acidic amino acid, like glutamic acid, phenylalanine, glutamine, hypothesis that adenohypophyseal acid phosphatase is tyrosine, leucin, valin, aspartic acid and asparagine. The related to thyrotropin secretion and that TRH is its presence of extrahypothalamic TRH-like peptides was reported in possible activator (Schreiber and Kmentova 1959, peripheral tissues including gastrointestinal tract, placenta, neural Schreiber et al. 1962). TRH precursor, human prepro- tissues, male reproductive system and certain endocrine tissues. TRH, consists of 242 amino acid residues, and contains Work deals with the biological function of TRH-like peptides in six separate copies of the TRH progenitor sequence different parts of organisms where various mechanisms may (Satoh and Mori 1994), which determine the primary serve for realisation of biological function of TRH-like peptides as structure of TRH as a tripeptide pyroglutamyl-histidinyl- negative feedback to the pituitary exerted by the TRH-like proline amide. The transcriptional unit of prepro-TRH is peptides, the role of pEEPam such as fertilization-promoting localized on chromosome 3 in humans (three exons peptide, the mechanism influencing the proliferative ability of interrupted by two introns) (Yamada et al.
    [Show full text]
  • Peptide Handbook a Guide to Peptide Design and Applications in Biomedical Research
    Peptide Handbook A Guide to Peptide Design and Applications in Biomedical Research First Edition www.GenScript.com GenScript USA Inc. 860 Centennial Ave. Piscataway, NJ 08854 USA Phone: 1-732-885-9188 Toll-Free: 1-877-436-7274 Fax: 1-732-885-5878 Table of Contents The Universe of Peptides Reliable Synthesis of High-Quality Peptides Molecular structure 3 by GenScript Characteristics 5 Categories and biological functions 8 Analytical methods 10 Application of Peptides Research in structural biology 12 Research in disease pathogenesis 12 Generating antibodies 13 FlexPeptideTM Peptide Synthesis Platform which takes advantage of the latest Vaccine development 14 peptide synthesis technologies generates a large capacity for the quick Drug discovery and development 15 synthesis of high-quality peptides in a variety of lengths, quantities, purities Immunotherapy 17 and modifications. Cell penetration-based applications 18 Anti-microorganisms applications 19 Total Quality Management System based on multiple rounds of MS and HPLC Tissue engineering and regenerative medicine 20 analyses during and after peptide synthesis ensures the synthesis of Cosmetics 21 high-quality peptides free of contaminants, and provides reports on peptide Food industry 21 solubility, quality and content. Synthesis of Peptides Diverse Delivery Options help customers plan their peptide-based research Chemical synthesis 23 according to their time schedule and with peace of mind. Microwave-assisted technology 24 ArgonShield™ Packing eliminates the experimental variation caused by Ligation technology 26 oxidization and deliquescence of custom peptides through an innovative Recombinant technology 28 Modifications packing and delivery technology. 28 Purification 30 Expert Support offered by Ph.D.-level scientists guides customers from Product identity and quality control 31 peptide design and synthesis to reconstitution and application.
    [Show full text]
  • Effect of the Natural Sweetener Xylitol on Gut Hormone Secretion and Gastric Emptying in Humans: a Pilot Dose-Ranging Study
    nutrients Article Effect of the Natural Sweetener Xylitol on Gut Hormone Secretion and Gastric Emptying in Humans: A Pilot Dose-Ranging Study Anne Christin Meyer-Gerspach 1,2,* , Jürgen Drewe 3, Wout Verbeure 4 , Carel W. le Roux 5, Ludmilla Dellatorre-Teixeira 5, Jens F. Rehfeld 6, Jens J. Holst 7 , Bolette Hartmann 7, Jan Tack 4, Ralph Peterli 8, Christoph Beglinger 1,2 and Bettina K. Wölnerhanssen 1,2,* 1 St. Clara Research Ltd. at St. Claraspital, 4002 Basel, Switzerland; [email protected] 2 Faculty of Medicine, University of Basel, 4001 Basel, Switzerland 3 Department of Clinical Pharmacology and Toxicology, University Hospital of Basel, 4001 Basel, Switzerland; [email protected] 4 Translational Research Center for Gastrointestinal Disorders, Catholic University of Leuven, 3000 Leuven, Belgium; [email protected] (W.V.); [email protected] (J.T.) 5 Diabetes Complications Research Centre, Conway Institute University College Dublin, 3444 Dublin, Ireland; [email protected] (C.W.l.R.); [email protected] (L.D.-T.) 6 Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark; [email protected] 7 Department of Biomedical Sciences and Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark; [email protected] (J.J.H.); [email protected] (B.H.) 8 Department of Surgery, Clarunis, St. Claraspital, 4002 Basel, Switzerland; [email protected] * Correspondence: [email protected] (A.C.M.-G.); [email protected] (B.K.W.); Tel.: +41-61-685-85-85 (A.C.M.-G.
    [Show full text]
  • What Is Pancreatic Polypeptide and What Does It Do?
    What is Pancreatic Polypeptide and what does it do? This document aims to evaluate current understanding of pancreatic polypeptide (PP), a gut hormone with several functions contributing towards the maintenance of energy balance. Successful regulation of energy homeostasis requires sophisticated bidirectional communication between the gastrointestinal tract and central nervous system (CNS; Williams et al. 2000). The coordinated release of numerous gastrointestinal hormones promotes optimal digestion and nutrient absorption (Chaudhri et al., 2008) whilst modulating appetite, meal termination, energy expenditure and metabolism (Suzuki, Jayasena & Bloom, 2011). The Discovery of a Peptide Kimmel et al. (1968) discovered PP whilst purifying insulin from chicken pancreas (Adrian et al., 1976). Subsequent to extraction of avian pancreatic polypeptide (aPP), mammalian homologues bovine (bPP), porcine (pPP), ovine (oPP) and human (hPP), were isolated by Lin and Chance (Kimmel, Hayden & Pollock, 1975). Following extensive observation, various features of this novel peptide witnessed its eventual classification as a hormone (Schwartz, 1983). Molecular Structure PP is a member of the NPY family including neuropeptide Y (NPY) and peptide YY (PYY; Holzer, Reichmann & Farzi, 2012). These biologically active peptides are characterized by a single chain of 36-amino acids and exhibit the same ‘PP-fold’ structure; a hair-pin U-shaped molecule (Suzuki et al., 2011). PP has a molecular weight of 4,240 Da and an isoelectric point between pH6 and 7 (Kimmel et al., 1975), thus carries no electrical charge at neutral pH. Synthesis Like many peptide hormones, PP is derived from a larger precursor of 10,432 Da (Leiter, Keutmann & Goodman, 1984). Isolation of a cDNA construct, synthesized from hPP mRNA, proposed that this precursor, pre-propancreatic polypeptide, comprised 95 residues (Boel et al., 1984) and is processed to produce three products (Leiter et al., 1985); PP, an icosapeptide containing 20-amino acids and a signal peptide (Boel et al., 1984).
    [Show full text]
  • Rfamide Peptides: Structure, Function, Mechanisms and Pharmaceutical Potential
    Pharmaceuticals 2011, 4, 1248-1280; doi:10.3390/ph4091248 OPEN ACCESS Pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review RFamide Peptides: Structure, Function, Mechanisms and Pharmaceutical Potential Maria Findeisen †, Daniel Rathmann † and Annette G. Beck-Sickinger * Institute of Biochemistry, Leipzig University, Brüderstraße 34, 04103 Leipzig, Germany; E-Mails: [email protected] (M.F.); [email protected] (D.R.) † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +49-341-9736900; Fax: +49-341-9736909. Received: 29 August 2011; in revised form: 9 September 2011 / Accepted: 15 September 2011 / Published: 21 September 2011 Abstract: Different neuropeptides, all containing a common carboxy-terminal RFamide sequence, have been characterized as ligands of the RFamide peptide receptor family. Currently, five subgroups have been characterized with respect to their N-terminal sequence and hence cover a wide pattern of biological functions, like important neuroendocrine, behavioral, sensory and automatic functions. The RFamide peptide receptor family represents a multiligand/multireceptor system, as many ligands are recognized by several GPCR subtypes within one family. Multireceptor systems are often susceptible to cross-reactions, as their numerous ligands are frequently closely related. In this review we focus on recent results in the field of structure-activity studies as well as mutational exploration of crucial positions within this GPCR system. The review summarizes the reported peptide analogs and recently developed small molecule ligands (agonists and antagonists) to highlight the current understanding of the pharmacophoric elements, required for affinity and activity at the receptor family.
    [Show full text]
  • Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions
    Molecular Pharmacology Fast Forward. Published on June 2, 2020 as DOI: 10.1124/mol.120.119388 This article has not been copyedited and formatted. The final version may differ from this version. File name: Opioid peptides v45 Date: 5/28/20 Review for Mol Pharm Special Issue celebrating 50 years of INRC Five decades of research on opioid peptides: Current knowledge and unanswered questions Lloyd D. Fricker1, Elyssa B. Margolis2, Ivone Gomes3, Lakshmi A. Devi3 1Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; E-mail: [email protected] 2Department of Neurology, UCSF Weill Institute for Neurosciences, 675 Nelson Rising Lane, San Francisco, CA 94143, USA; E-mail: [email protected] 3Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, Annenberg Downloaded from Building, One Gustave L. Levy Place, New York, NY 10029, USA; E-mail: [email protected] Running Title: Opioid peptides molpharm.aspetjournals.org Contact info for corresponding author(s): Lloyd Fricker, Ph.D. Department of Molecular Pharmacology Albert Einstein College of Medicine 1300 Morris Park Ave Bronx, NY 10461 Office: 718-430-4225 FAX: 718-430-8922 at ASPET Journals on October 1, 2021 Email: [email protected] Footnotes: The writing of the manuscript was funded in part by NIH grants DA008863 and NS026880 (to LAD) and AA026609 (to EBM). List of nonstandard abbreviations: ACTH Adrenocorticotrophic hormone AgRP Agouti-related peptide (AgRP) α-MSH Alpha-melanocyte stimulating hormone CART Cocaine- and amphetamine-regulated transcript CLIP Corticotropin-like intermediate lobe peptide DAMGO D-Ala2, N-MePhe4, Gly-ol]-enkephalin DOR Delta opioid receptor DPDPE [D-Pen2,D- Pen5]-enkephalin KOR Kappa opioid receptor MOR Mu opioid receptor PDYN Prodynorphin PENK Proenkephalin PET Positron-emission tomography PNOC Pronociceptin POMC Proopiomelanocortin 1 Molecular Pharmacology Fast Forward.
    [Show full text]
  • Inhibition of Gastrin-Releasing Peptide Attenuates Phosphate-Induced Vascular Calcification
    cells Article Inhibition of Gastrin-Releasing Peptide Attenuates Phosphate-Induced Vascular Calcification Hyun-Joo Park 1,2, Yeon Kim 1,2, Mi-Kyoung Kim 1, Jae Joon Hwang 3, Hyung Joon Kim 1,2 , Soo-Kyung Bae 2,4 and Moon-Kyoung Bae 1,2,* 1 Department of Oral Physiology, BK21 PLUS Project, School of Dentistry, Pusan National University, Yangsan 50610, Korea; [email protected] (H.-J.P.); [email protected] (Y.K.); [email protected] (M.-K.K.); [email protected] (H.J.K) 2 Dental and Life Science Institute, School of Dentistry, Pusan National University, Yangsan 50610, Korea; [email protected] 3 Department of Oral and Maxillofacial Radiology, School of Dentistry, Pusan National University, Dental Research Institute, Yangsan 50610, Korea; [email protected] 4 Department of Dental Pharmacology, BK21 PLUS Project, School of Dentistry, Pusan National University, Yangsan 50610, Korea * Correspondence: [email protected]; Tel.: +82-51-510-8239 Received: 29 January 2020; Accepted: 13 March 2020; Published: 17 March 2020 Abstract: Vascular calcification is the pathological deposition of calcium/phosphate in the vascular system and is closely associated with cardiovascular morbidity and mortality. Here, we investigated the role of gastrin-releasing peptide (GRP) in phosphate-induced vascular calcification and its potential regulatory mechanism. We found that the silencing of GRP gene and treatment with the GRP receptor antagonist, RC-3095, attenuated the inorganic phosphate-induced calcification of vascular smooth muscle cells (VSMCs). This attenuation was caused by inhibiting phenotype change, apoptosis and matrix vesicle release in VSMCs. Moreover, the treatment with RC-3095 effectively ameliorated phosphate-induced calcium deposition in rat aortas ex vivo and aortas of chronic kidney disease in mice in vivo.
    [Show full text]
  • Monoclonal Antibody to Adrenocorticotropic Hormone (ACTH) (1-24) - Purified
    OriGene Technologies, Inc. OriGene Technologies GmbH 9620 Medical Center Drive, Ste 200 Schillerstr. 5 Rockville, MD 20850 32052 Herford UNITED STATES GERMANY Phone: +1-888-267-4436 Phone: +49-5221-34606-0 Fax: +1-301-340-8606 Fax: +49-5221-34606-11 [email protected] [email protected] AM50155PU-N Monoclonal Antibody to Adrenocorticotropic Hormone (ACTH) (1-24) - Purified Alternate names: Adrenocorticotropic hormone, Corticotropin, POMC Quantity: 0.2 mg Concentration: 0.2 mg/ml Background: ACTH (Adrenocorticotrophic hormone) is produced and secreted by the anterior pituitary gland, and is a key component of the hypothalamic-pituitary-adrenal axis. ACTH is synthesized from the precursor molecule pre-opiomelanocorin (POMC). POMC undergoes proteolytic cleavages and processing to generate not only ACTH but also a number of other small biologically active peptides including alpha-MSH and beta- endorphin, all in cell type specific manners. The production of ACTH is triggered by biological stress. ACTH, in turn, then stimulates the secretion of corticosteroids by the adrenal cortex. The half-life of ACTH in human blood is only about ten minutes. An excess of ACTH can cause Cushing's syndrome whereas ACTH deficiency can result in secondary adrenal insufficiency. ACTH consists of 39 amino acids (aa), and can be proteolytically cleaved into different active fragments including CLIP (corticotropin-like intermediate lobe peptide), consisting of aa 17-39, which stimulates insulin production. Synacthen is an active synthetic form of ACTH, corresponding to the first 24 aa, which is used to conduct ACTH stimulation tests. Uniprot ID: P01189 NCBI: 9606 GeneID: 5443 Host / Isotype: Mouse / IgG1 Recommended Isotype SM10P (for use in human samples), SM20P (for use in rat samples), AM03095PU-N Controls: Clone: SPM333 Immunogen: Synthetic peptide corresponding to aa1-24 of human ACTH.
    [Show full text]
  • REVIEW the Role of Rfamide Peptides in Feeding
    3 REVIEW The role of RFamide peptides in feeding David A Bechtold and Simon M Luckman Faculty of Life Sciences, University of Manchester, 1.124 Stopford Building, Oxford Road, Manchester M13 9PT, UK (Requests for offprints should be addressed to D A Bechtold; Email: [email protected]) Abstract In the three decades since FMRFamide was isolated from the evolution. Even so, questions remain as to whether feeding- clam Macrocallista nimbosa, the list of RFamide peptides has related actions represent a primary function of the RFamides, been steadily growing. These peptides occur widely across the especially within mammals. However, as we will discuss here, animal kingdom, including five groups of RFamide peptides the study of RFamide function is rapidly expanding and with identified in mammals. Although there is tremendous it so is our understanding of how these peptides can influence diversity in structure and biological activity in the RFamides, food intake directly as well as related aspects of feeding the involvement of these peptides in the regulation of energy behaviour and energy expenditure. balance and feeding behaviour appears consistently through Journal of Endocrinology (2007) 192, 3–15 Introduction co-localised with classical neurotransmitters, including acetyl- choline, serotonin and gamma-amino bulyric acid (GABA). The first recognised member of the RFamide neuropeptide Although a role for RFamides in feeding behaviour was family was the cardioexcitatory peptide, FMRFamide, first suggested over 20 years ago, when FMRFamide was isolated from ganglia of the clam Macrocallista nimbosa (Price shown to be anorexigenic in mice (Kavaliers et al. 1985), the & Greenberg 1977). Since then a large number of these question of whether regulating food intake represents a peptides, defined by their carboxy-terminal arginine (R) and primary function of RFamide signalling remains.
    [Show full text]
  • The Relationship Between Different C-Peptide Level and Insulin Dose of Insulin Pump Yihan Wei1,Liquan1, Ting Zhou1,Guolidu1 and Sheng Jiang 1
    Wei et al. Nutrition and Diabetes (2021) 11:7 https://doi.org/10.1038/s41387-020-00148-7 Nutrition & Diabetes ARTICLE Open Access The relationship between different C-peptide level and insulin dose of insulin pump Yihan Wei1,LiQuan1, Ting Zhou1,GuoliDu1 and Sheng Jiang 1 Abstract Background: This study aims to explore the insulin requirement profiles, and analyze the related factors of type-2 diabetes mellitus (T2DM) with different C-peptide levels on insulin pump therapy. Methods: A retrospective study was conducted on 271 T2DM patients treated with insulin pumps from 2016 to 2018. These patients were divided into groups according to the ratio of C-peptide at 2 h after meals to fasting C-peptide (C2h/C0), and the dosage of insulin and influencing factors were analyzed. Results: In comparing group A (C2h/C0 < 2.5) with group B (C2h/C0 ≥ 2.5), the percentage of the base amount in total (%TBa, 0.50 ± 0.06) in group A was higher than that in group B (0.48 ± 0.05) (P < 0.05). Furthermore, there was a correlation between C2h/C0 and waist circumference, HbA1c, Fasting Plasma Glucose (FPG) and Blood glucose 2 h after meal (2hPG) (r = −0.137, −0.154, −0.471, and −0.172; all, P < 0.05). The multiple linear regression analysis revealed that BMI and FPG were independent factors of %TBa (β′ = 0.124 and 0.144; all, P < 0.05), and BMI and FPG were independent factors of C2h/C0 (β′ = −0.134 and −0.502; all, P < 0.05). Conclusions: The basal premeal dose ratio of T2DM with different C-peptide levels differs during intensive insulin pump therapy.
    [Show full text]
  • Views of the NIDA, NINDS Or the National Summed Across the Three Auditory Forebrain Lobule Sec- Institutes of Health
    Xie et al. BMC Biology 2010, 8:28 http://www.biomedcentral.com/1741-7007/8/28 RESEARCH ARTICLE Open Access The zebra finch neuropeptidome: prediction, detection and expression Fang Xie1, Sarah E London2,6, Bruce R Southey1,3, Suresh P Annangudi1,6, Andinet Amare1, Sandra L Rodriguez-Zas2,3,5, David F Clayton2,4,5,6, Jonathan V Sweedler1,2,5,6* Abstract Background: Among songbirds, the zebra finch (Taeniopygia guttata) is an excellent model system for investigating the neural mechanisms underlying complex behaviours such as vocal communication, learning and social interactions. Neuropeptides and peptide hormones are cell-to-cell signalling molecules known to mediate similar behaviours in other animals. However, in the zebra finch, this information is limited. With the newly-released zebra finch genome as a foundation, we combined bioinformatics, mass-spectrometry (MS)-enabled peptidomics and molecular techniques to identify the complete suite of neuropeptide prohormones and final peptide products and their distributions. Results: Complementary bioinformatic resources were integrated to survey the zebra finch genome, identifying 70 putative prohormones. Ninety peptides derived from 24 predicted prohormones were characterized using several MS platforms; tandem MS confirmed a majority of the sequences. Most of the peptides described here were not known in the zebra finch or other avian species, although homologous prohormones exist in the chicken genome. Among the zebra finch peptides discovered were several unique vasoactive intestinal and adenylate cyclase activating polypeptide 1 peptides created by cleavage at sites previously unreported in mammalian prohormones. MS-based profiling of brain areas required for singing detected 13 peptides within one brain nucleus, HVC; in situ hybridization detected 13 of the 15 prohormone genes examined within at least one major song control nucleus.
    [Show full text]